Can you take Dipyridamole with Plavix?

Dipyridamole has a moderate potential interaction with Arrhythmia.

Serious adverse reactions associated with the administration of intravenous dipyridamole have included cardiac death, fatal and non- fatal myocardial infarction, ventricular fibrillation, symptomatic ventricular tachycardia, stroke, transient cerebral ischemia, seizures, anaphylactoid reaction and bronchospasm. There have been reported cases of asystole, sinus node arrest, sinus node depression and conduction block. Patients with abnormalities of cardiac impulse formation/conduction or severe coronary artery disease may be at increased risk for these events. Caution is recommended.

Dipyridamole has a major potential interaction with Asthma.

Dipyridamole is a phosphodiesterase inhibitor and can exacerbate bronchospasm, particularly in patients with reactive airway disease and/or chronic obstructive pulmonary disease (COPD). Therapy with dipyridamole is contraindicated in patients with active wheezing and should be administered cautiously in patients with asthma or COPD.

The clopidogrel in Plavix has a major potential interaction with Bleeding Disorder.

Clopidogrel is contraindicated in patients with active pathological bleeding such as peptic ulcer or intracranial hemorrhage.

Dipyridamole has a major potential interaction with COPD.

Dipyridamole is a phosphodiesterase inhibitor and can exacerbate bronchospasm, particularly in patients with reactive airway disease and/or chronic obstructive pulmonary disease (COPD). Therapy with dipyridamole is contraindicated in patients with active wheezing and should be administered cautiously in patients with asthma or COPD.

Dipyridamole has a moderate potential interaction with Hypotension.

Dipyridamole can cause peripheral vasodilation. Therapy with dipyridamole should be administered cautiously in patients with hypotension.

The clopidogrel in Plavix has a moderate potential interaction with Liver Disease.

The pharmacokinetic disposition of clopidogrel in patients with liver disease has not been established. Clopidogrel undergoes biotransformation to an active metabolite that has not yet been isolated and an inactive form that represents approximately 85% of circulating clopidogrel. The metabolic and therapeutic activity of clopidogrel may be altered in patients with hepatic impairment and should be administered cautiously in patients with severe hepatic dysfunction. Clinical monitoring of hepatic function and bleeding activity is recommended.

Dipyridamole has a moderate potential interaction with Myasthenia Gravis.

Myasthenia gravis patients receiving therapy with cholinesterase inhibitors may experience worsening of their disease in the presence of dipyridamole. Caution should be exercised with these patients.

The clopidogrel in Plavix has a minor potential interaction with Renal Dysfunction.

Clopidogrel is partially eliminated by the kidney. Approximately 50% of clopidogrel is excreted in the urine and 45% in the feces. Plasma concentrations of the inactive metabolite and the degree of platelet inhibition are reduced in patients with severe renal impairment (creatinine clearance of 5-15 mL/min). However, bleeding times in patients with severe renal impairment did not differ from those with normal renal function. No dosage adjustment is recommended for patients with compromised renal function.